Public Employees Retirement Association of Colorado trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 687,576 shares of the pharmaceutical company’s stock after selling 760 shares during the quarter. Public Employees Retirement Association of Colorado owned 0.27% of Vertex Pharmaceuticals worth $116,489,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of VRTX. BlackRock Inc. raised its holdings in Vertex Pharmaceuticals by 2.6% during the 2nd quarter. BlackRock Inc. now owns 20,708,669 shares of the pharmaceutical company’s stock worth $3,797,554,000 after buying an additional 532,371 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 0.9% in the second quarter. Vanguard Group Inc. now owns 19,661,800 shares of the pharmaceutical company’s stock worth $3,605,582,000 after buying an additional 180,239 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Vertex Pharmaceuticals by 9.4% in the second quarter. Renaissance Technologies LLC now owns 5,555,817 shares of the pharmaceutical company’s stock worth $1,018,826,000 after buying an additional 477,100 shares during the period. Invesco Ltd. increased its position in shares of Vertex Pharmaceuticals by 9.0% in the second quarter. Invesco Ltd. now owns 4,063,908 shares of the pharmaceutical company’s stock worth $745,238,000 after acquiring an additional 335,938 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Vertex Pharmaceuticals by 1.1% in the second quarter. Northern Trust Corp now owns 2,943,780 shares of the pharmaceutical company’s stock worth $539,830,000 after acquiring an additional 33,009 shares in the last quarter. 94.87% of the stock is owned by institutional investors.
In related news, Director Sangeeta N. Bhatia sold 8,379 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $166.80, for a total value of $1,397,617.20. Following the transaction, the director now directly owns 7,810 shares of the company’s stock, valued at approximately $1,302,708. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Ourania Tatsis sold 188 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $169.11, for a total value of $31,792.68. Following the completion of the sale, the senior vice president now owns 7,696 shares of the company’s stock, valued at $1,301,470.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 290,475 shares of company stock worth $56,792,441. 0.70% of the stock is currently owned by company insiders.
Several equities research analysts recently commented on VRTX shares. Robert W. Baird set a $210.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 21st. Piper Jaffray Companies lifted their price objective on shares of Vertex Pharmaceuticals from $230.00 to $247.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. BMO Capital Markets boosted their target price on shares of Vertex Pharmaceuticals to $248.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. ValuEngine cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cowen reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $219.07.
Shares of VRTX stock opened at $220.79 on Tuesday. The firm has a market cap of $57.02 billion, a P/E ratio of 78.02, a PEG ratio of 2.03 and a beta of 1.49. The stock’s 50-day moving average is $200.93 and its two-hundred day moving average is $181.81. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $151.80 and a fifty-two week high of $223.73. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.44 and a quick ratio of 3.32.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.36. The firm had revenue of $949.83 million for the quarter, compared to the consensus estimate of $942.90 million. Vertex Pharmaceuticals had a return on equity of 20.33% and a net margin of 59.24%. The firm’s revenue was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.09 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 3.72 EPS for the current year.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Article: FTSE 100 Index
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.